Affiliations 

  • 1 FCTI Biotech R&D GmbH Klosterstrasse 205, 67480 Edenkoben, Germany
  • 2 Baden R&D Laboratories GmbH Klosterstrasse 205, 67480 Edenkoben, Germany
Future Sci OA, 2020 Oct 29;7(2):FSO648.
PMID: 33437514 DOI: 10.2144/fsoa-2020-0142

Abstract

The immune system is a complex network of specialized cells and organs that recognises and reacts against foreign pathogens while remaining unresponsive to host tissues. This ability to self-tolerate is known as immunological tolerance. Autoimmune disease occurs when the immune system fails to differentiate between self and non-self antigens and releases autoantibodies to attack our own cells. Anti-idiotypic (anti-ID) antibodies are important in maintaining a balanced idiotypic regulatory network by neutralising and inhibiting the secretion of autoantibodies. Recently, anti-ID antibodies have been advanced as an alternative form of immunotherapy as they can specifically target autoantibodies, cause less toxicity and side effects, and could provide long-lasting immunity. This review article discusses the immunomodulatory potential of anti-ID antibodies for the treatment of autoimmune diseases.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.